Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cardiome Pharma Corp Receives Approval For Brinavess In Turkey


Wednesday, 25 Sep 2013 08:49am EDT 

Cardiome Pharma Corp. announced that Brinavess (vernakalant intravenous) has been approved in Turkey by the Turkish Ministry of Health for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults. The Turkish Ministry of Health oversees the regulation of medicines in Turkey. 

Company Quote

9.04
0.48 +5.61%
26 Dec 2014